ArriVent BioPharma (AVBP) Change in Accured Expenses (2023 - 2026)

ArriVent BioPharma has disclosed Change in Accured Expenses across 4 years of filings, most recently posting -$3.8 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$3.8 million, up 21.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.7 million (up 213.61% YoY), and the FY2025 annual result was $6.7 million, up 4.55% from the prior year.
• Change in Accured Expenses came in at -$3.8 million for Q1 2026 at ArriVent BioPharma, down from $4.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.0 million in Q2 2025 to a low of -$4.9 million in Q1 2025.
• The 4-year median for Change in Accured Expenses is $1.6 million (2023), against an average of $828615.4.
• Across the five-year window, Change in Accured Expenses soared 282.23% in 2024 and slumped 406.65% in 2025, its largest moves.
• ArriVent BioPharma's Change in Accured Expenses stood at $1.6 million in 2023, then surged by 81.71% to $3.0 million in 2024, then surged by 49.04% to $4.4 million in 2025, then sank by 186.45% to -$3.8 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.8 million (Q1 2026), $4.4 million (Q4 2025), and $91000.0 (Q3 2025), per Business Quant data.